Strengthening healthcare resilience through local pharmaceutical manufacturing

Healthcare resilience is often discussed in terms of hospitals, doctors, infrastructure and public funding. Yet one of its most important foundations sits further upstream: the ability of a country to reliably produce, procure and distribute quality medicines when they are needed most.

For Sri Lanka, this is no longer a theoretical issue. The economic crisis, foreign exchange constraints and global supply chain disruptions have shown how quickly access to medicines can be affected when systems are heavily import-dependent. In this context, local pharmaceutical manufacturing is not just an industrial priority. It is a core component of national healthcare security.

Sri Lanka’s reliance on imported medicines has long exposed the healthcare system to external risks, from currency volatility to geopolitical shifts. Strengthening domestic manufacturing can help mitigate these vulnerabilities by improving availability, reducing lead times and enabling more consistent access to essential treatments. This is particularly important for chronic conditions where continuity of care is critical, where even short disruptions can have direct consequences for patients.

From supply security to economic stability

Local pharmaceutical manufacturing is not only about access. It also has a clear economic dimension. It supports skilled employment, builds technical capability and reduces pressure on foreign exchange reserves.

For a country managing tight fiscal and external balances, the ability to produce even a portion of essential medicines locally contributes to greater economic stability. Over time, it also creates the potential to move beyond import substitution towards export capability in selected product categories.

At the same time, resilience depends on more than just output. Quality, regulation and traceability remain central. Strong manufacturing standards and regulatory oversight are essential to ensure that locally produced medicines meet the expectations of both healthcare professionals and patients. Without this foundation, scale alone does not translate into trust.

Aligning policy with long-term needs

The policy environment will play a defining role in determining how far and how fast the sector can grow. Recent measures, including tax concessions on pharmaceutical inputs and broader support through the national budget, indicate a recognition of the importance of local manufacturing.

However, consistency is key. Manufacturers require a stable and predictable policy framework to make long-term investments in facilities, technology and skills. This includes clear regulatory pathways, procurement systems that recognise local capacity, and incentives that are aligned with national healthcare priorities rather than short-term cost considerations.

In parallel, local manufacturers have begun building capability in specific therapeutic areas where continuity of supply is particularly important. Strengthening these areas further will require sustained investment and closer coordination between industry and policymakers.

Building resilience ahead of the next disruption

Healthcare resilience is built before a crisis, not during one. A more balanced approach that combines global sourcing with stronger domestic capability can reduce vulnerability and improve responsiveness when disruptions occur.

Local pharmaceutical manufacturing will not replace imports entirely, nor should it. But a stronger domestic base can provide a critical buffer, ensuring that essential medicines remain available even under strain.

For Sri Lanka, the path forward lies in treating pharmaceutical manufacturing not just as an industry, but as a strategic component of national resilience. Done right, it strengthens both the healthcare system and the broader economy, while improving long-term security for patients across the country.

(The author is the CEO of Lina Manufacturing Ltd., and Executive Director of Sunshine Healthcare)